A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab, as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13 18 BEAT-meso trial.

Background: The currently approved frontline treatments for diffuse pleural mesothelioma (DPM) are ipilimumab-nivolumab or platinum-pemetrexed. The addition of bevacizumab to chemotherapy improves overall survival (OS). While single-agent immunotherapy or chemotherapy-immunotherapy combinations are superior to chemotherapy monotherapy, there is a potential for synergistic triple combination of chemotherapy, bevacizumab, and immunotherapy.

Pulp sensibility responses following complete and partial pulpotomy in mature permanent molars with carious pulpal exposure and symptomatic irreversible pulpitis: Analysis of pooled data from three randomized clinical trials.

Aim: The objective of pulpotomy is to preserve the pulp vitality. However, the assessment of pulpal status following pulpotomy is often overlooked. This retrospective analysis aimed to compare the pulp responses to EPT (Electric pulp test) and cold test in mature permanent molars that have undergone either complete pulpotomy (CP) or partial pulpotomy (PP) for managing carious pulpal exposure and symptomatic irreversible pulpitis (SIP) and completed 12 months follow-up.

An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer.

Introduction: The EORTC-Lung Cancer Group initiated a Delphi consensus process to establish a consensual definition of resectable stage III non-small cell lung cancer (NSCLC) for the use in clinical trials, including a systematic review, survey, and review of clinical cases. Here, the survey results are presented, aimed to identify areas of controversy.

Methods: A survey was distributed among the members of six international organizations related to lung cancer.